Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06259292 · ClinicalTrials.gov registry record

Comprehensive HHT Outcomes Registry of the United States (CHORUS)

A clinical trial of Hereditary Hemorrhagic Telangiectasia and Epistaxis, sponsored by Cure HHT.

Recruiting
Registry status
10,000
Enrollment target
16
Study locations

NCT06259292 is a study of Hereditary Hemorrhagic Telangiectasia and Epistaxis that is actively recruiting participants, run by Cure HHT. The registered enrollment target is 10,000 participants, above the 362-participant average among 7 other Hereditary Hemorrhagic Telangiectasia trials with a reported enrollment target (2662% higher). The trial reports 16 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06259292, a study of Hereditary Hemorrhagic Telangiectasia and Epistaxis, is actively recruiting participants, sponsored by Cure HHT.

RECRUITING
Registry status
10,000 participants
Enrollment target
16
Study locations

Study Summary

The Comprehensive HHT Outcomes Registry of the United States (CHORUS) is an observational registry of patients diagnosed with Hereditary Hemorrhagic Telangiectasia (HHT). The purpose of this study is to better understand HHT, the symptoms and complications it causes, and the impact the disease has on people's lives. The investigators will collect long-term information about the participant, allowing us to understand how the disease changes over time, and what factors can influence those changes. Ultimately, this should help improve treatments for the disease. Another important goal of the study is to provide a way to contact people to participate in future clinical trials and other research. The registry will be a centralized resource for recruitment for clinical trials. People in the registry will not be obligated to join any of these additional studies, but if interested, can agree to be contacted if they may be eligible for a study. Participants will: * Be asked to provide permission to collect information from their medical records, including things like demographic information, diagnosis information, family history, test results, treatment information, symptoms, complications, lifestyle and other relevant medical information. * Be asked study-related questions by phone or at a clinic visit. * Be asked study-related questions every year after enrollment for up to 10 years or until the study ends. A member of the study team will communicate with participants by phone or at clinic visits to collect information regarding any changes to their health over the previous year/s including new test results, treatment information, symptoms, and complications from HHT.

Conditions Studied

Hereditary Hemorrhagic Telangiectasia Epistaxis Arteriovenous Malformations GastroIntestinal Bleeding Telangiectasia Vascular Malformation Cerebral Arteriovenous Malformations

Study Locations (16)

California

  • University of California, Los Angeles - Los Angeles
  • University of California, San Francisco - San Francisco

Alabama

  • University of Alabama at Birmingham - Birmingham

Colorado

  • University of Colorado, Denver - Aurora

Connecticut

  • Yale University - New Haven

Georgia

  • Augusta University - Augusta

Massachusetts

  • Massachusetts General Hospital - Boston

Minnesota

  • Mayo Clinic - Rochester

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 10,000 participants
Start Date 2023-11-13
Est. Completion 2033-11

Sponsor

Cure HHT

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06259292

The ClinicalTrials.gov registry entry for NCT06259292 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 10,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 362-participant average among 7 other Hereditary Hemorrhagic Telangiectasia trials with a reported enrollment target (2662% higher). The listed sponsor is Cure HHT, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Hereditary Hemorrhagic Telangiectasia appearing as the primary indexed condition, and to 0 interventions.

NCT06259292 reports 16 study locations spanning 15 distinct geographic areas - top geographies include California, Alabama, Colorado.

Frequently Asked Questions

What is clinical trial NCT06259292 about?

NCT06259292 is a clinical study titled "Comprehensive HHT Outcomes Registry of the United States (CHORUS)". The Comprehensive HHT Outcomes Registry of the United States (CHORUS) is an observational registry of patients diagnosed with Hereditary Hemorrhagic Telangiectasia (HHT). The purpose of this study is to better understand HHT, the symptoms and complications it causes, and the impact the disease has o...

What is the current status of trial NCT06259292?

This trial is currently recruiting. The enrollment target is 10,000 participants. The study started on 2023-11-13. Estimated completion is 2033-11.

What conditions does trial NCT06259292 study?

This clinical trial studies the following conditions: Hereditary Hemorrhagic Telangiectasia, Epistaxis, Arteriovenous Malformations, GastroIntestinal Bleeding, Telangiectasia.

Who is sponsoring clinical trial NCT06259292?

This trial is sponsored by Cure HHT, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06259292 being conducted?

This trial has 16 study locations across Alabama, California, Colorado, Connecticut, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hereditary Hemorrhagic Telangiectasia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hereditary Hemorrhagic Telangiectasia

All registered trials for this condition

Epistaxis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.